Expertise in
42
conditions

Dr. Brett L. Gourley

Hematology Oncology
400 East 5th Avenue, 
Spokane, WA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
42
conditions
400 East 5th Avenue, 
Spokane, WA 

Overview

Brett Gourley is a Hematologist Oncology provider practicing medicine in Spokane, Washington.

Dr. Gourley is highly rated in 42 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Monoclonal Gammopathy of Undetermined Significance (MGUS), Paget Disease of the Breast, and Pleuropulmonary Blastoma.

He is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 4 clinical trials. Dr. Gourley is currently accepting new patients.

Specialties

Hematology Oncology

Hospital Affiliations

Tacoma General Allenmore Hospital
Deaconess Medical Center
Kootenai Health
Providence Mount Carmel Hospital
Multicare Valley Hospital

Languages Spoken

English
Estonian
Filipino
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Moda Health
  • EPO
  • PPO
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

400 East 5th Avenue, Spokane, WA 99202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 10, 2026
Intervention Type: Combination product, Drug
Study Drugs: Tazemetostat, Lenalidomide, Rituximab
Study Phase: Phase 3
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: July 23, 2026
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin, Daunorubicin, Cytarabine
Study Phase: Phase 2
A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)
A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)
Enrollment Status: Active_not_recruiting
Publish Date: June 12, 2026
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pomalidomide, Dexamethasone, Bortezomib
Study Phase: Phase 3
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
Enrollment Status: Terminated
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Study Phase: Phase 3
View 3 Less Clinical Trials

2 Total Publications

Systemic coagulation is activated in patients with meningioma and glioblastoma.
Systemic coagulation is activated in patients with meningioma and glioblastoma.
Journal: Journal of neuro-oncology
Published: August 23, 2021
Similar Doctors
Expertise in
26
conditions
Dr. Jay L. Wittenkeller
Hematology Oncology
Expertise in
26
conditions
Dr. Jay L. Wittenkeller
Hematology Oncology
Referral may be required
Before you request
400 East 5th Avenue, 
Spokane, WA 
 (0.1 miles away)
509-838-2531
Languages Spoken:
English, Bengali, French, Korean, Spanish, Thai, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Jay Wittenkeller is a Hematologist Oncology provider practicing medicine in Spokane, Washington. Dr. Wittenkeller is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Myelodysplastic Syndrome (MDS), and Anemia. Dr. Wittenkeller is currently accepting new patients.

Expertise in
11
conditions
Dr. Corliss L. Newman
Hematology Oncology
Expertise in
11
conditions
Dr. Corliss L. Newman
Hematology Oncology
Referral may be required
Before you request
400 East 5th Avenue, 
Spokane, WA 
 (0.1 miles away)
509-838-2531
Languages Spoken:
English, Arabic, Filipino, Spanish, Thai
See accepted insurances
Accepting New Patients
Offers Telehealth

Corliss Newman is a Hematologist Oncology provider practicing medicine in Spokane, Washington. Dr. Newman is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndrome (MDS), Anemia, and Pleuropulmonary Blastoma. Dr. Newman is currently accepting new patients.

Expertise in
5
conditions
Dr. Brenen P. Swofford
Hematology Oncology
Expertise in
5
conditions
Dr. Brenen P. Swofford
Hematology Oncology
Referral may be required
Before you request
605 East Holland Avenue, 
Spokane, WA 
 (7.1 miles away)
509-228-1000
Experience:
10+ years
Languages Spoken:
English, Farsi
See accepted insurances
Accepting New Patients
Offers Telehealth

Brenen Swofford is a Hematologist Oncology provider practicing medicine in Spokane, Washington. He has been practicing medicine for over 10 years. Dr. Swofford is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Melanoma, Dehydration, Endometrial Stromal Sarcoma, and Malignant Mixed Mullerian Tumor. Dr. Swofford is currently accepting new patients.

Frequently Asked Questions about Dr. Brett L. Gourley

How do I make an appointment with Dr. Brett L. Gourley?

You can book an appointment with Dr. Brett L. Gourley by calling their office at 509-838-2531. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Brett L. Gourley a top-rated expert for Thrombocytopenia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Brett L. Gourley is classified as an Distinguished expert for Thrombocytopenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Brett L. Gourley specialize in?

While Dr. Brett L. Gourley is a Hematology Oncology, they have specific expertise in Thrombocytopenia, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Brett L. Gourley participate in research or clinical trials?

Yes. Dr. Brett L. Gourley has published 2 articles and abstracts on conditions like Thrombocytopenia. You can view a list of Dr. Brett L. Gourley's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Brett L. Gourley accept my insurance?

Dr. Brett L. Gourley accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 509-838-2531 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gourley's expertise for a condition
ConditionClose
    View All 36 Advanced Conditions
    View All 97 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile